Kos Biotechnology Invests in Golden Age Health for Rare Disease Access
Kos Biotechnology Partners has made a strategic investment in Golden Age Health, a firm co-founded by former Biogen CEO Michel Vounatsos, to expand rare disease therapies globally.
Kos Biotechnology Partners, a life sciences investment firm operating across U.S. and European markets, has announced a strategic investment in Golden Age Health, targeting broader global access to treatments for rare diseases, according to a statement released Monday.
Golden Age Health is co-founded and chaired by Michel Vounatsos, who previously served as chief executive of Biogen and as president of Merck. The company is headquartered across multiple regions, with a presence in New York, Athens, and Singapore, positioning it to pursue an international approach to rare disease therapy development and distribution.
Read more Perpetua Resources Wins Up to $40M Army Deal for Tungsten Supply →
The partnership between Kos and Golden Age Health reflects a broader trend in life sciences investment, where firms are increasingly focusing on underserved patient populations with limited treatment options. Rare diseases, by definition affecting small patient groups, often receive less commercial attention from large pharmaceutical companies, creating an opening for specialized investors and developers.
Kos describes itself as a bridge between U.S. and European life sciences ecosystems, and the Golden Age Health investment appears consistent with that cross-regional mandate. The involvement of a veteran industry leader with Vounatsos's profile signals confidence in the venture's strategic direction and its potential to navigate complex regulatory environments across multiple jurisdictions.
Financial terms of the investment were not disclosed. Continue reading at All Financial Services & Investing.
